TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04969068
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
Study: NCT06007222
Drug: Aspirin group
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
Study: NCT06249997
Drug: Leniolisib
Normalized name: Leniolisib
DrugBank: Leniolisib (DB16217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
Study: NCT05193721
Drug: SHR-1901
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
Study: NCT04786470
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine infusion via transversus abdominis plane catheter.
Study: NCT04786470
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline infusion via transversus abdominis plane catheter.
Study: NCT06122181
Drug: HS-10384 tablets
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of HS-10384 orally in a fasting state
Study: NCT06224127
Drug: Active c tactile fiber stimulation
Normalized name: fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair brushes that activate c tactile fibers
Study: NCT00002354
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002354
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05585307
Drug: GS-1720
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05585307
Drug: Standard of Care (Substudy 02)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC
Study: NCT05585307
Drug: GS-6212
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05686863
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remazolam for sedation in children undergoing bidirectional endoscopy
Study: NCT05686863
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine
Study: NCT05686863
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol
Study: NCT03612466
Drug: 153Sm-DOTMP
Normalized name: 153sm-dotmp
DrugBank: DOTMP SM-153 (DB18484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
Study: NCT03612466
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
Study: NCT04864821
Drug: Targeting CD276 CAR T cells
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeting CD276 autologous chimeric antigen receptor T cells
Study: NCT03612466
Drug: Mozobil
Normalized name: Mozobil
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
Study: NCT04799743
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
Study: NCT05376761
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
Study: NCT05467852
Drug: didroxyprogesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
Study: NCT04854759
Drug: Amantadine Hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, capsule
Study: NCT05275465
Drug: HH-006
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dose levels of HH-006
Study: NCT05381454
Drug: Mitoquinone/mitoquinol mesylate
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoquinone/mitoquinol mesylate
Study: NCT05073679
Drug: Naltrexone Hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg x 3 days then 50mg a day thereafter
Study: NCT04632459
Drug: pembrolizumab plus ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles.
Study: NCT05594381
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles).
Study: NCT06364787
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study: NCT04683796
Drug: 100% Autologous platelet rich plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Study: NCT04243629
Drug: Pramlintide Acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
Study: NCT04706897
Drug: Dexmedetomidine, ketamine and lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
Study: NCT04487808
Drug: Pecan
Normalized name: PECAN
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
Study: NCT05353205
Drug: Flumatinib mesylate tablets (400mg)
Normalized name: eprosartan
DrugBank: Flumatinib (DB11904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
Study: NCT05353205
Drug: Flumatinib mesylate tablets (600mg)
Normalized name: eprosartan
DrugBank: Flumatinib (DB11904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
Study: NCT04931368
Drug: Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: De-escalated induction treatment with R/HD-MTX and two courses of MATRix
Study: NCT00338546
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05050214
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
Study: NCT00338546
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05959759
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
Study: NCT06341686
Drug: Letermovir 480 MG
Normalized name: letermovir 480 MG
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
Study: NCT06341686
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
Study: NCT05133323
Drug: Lu AG09222
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG09222 will be administered per schedule specified in the arm.
Study: NCT05484414
Drug: SRP-3D (diethylamide)
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Study: NCT05162443
Drug: adagrasib (MRTX849)
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Study: NCT00337090
Drug: YM178
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06225973
Drug: TL-925
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-925 is an eye drop.
Study: NCT05621447
Drug: TAS-303, [14C]TAS-303
DrugBank: TAS-303 (DB18808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration on day 1
Study: NCT00215891
Drug: PEG-Interferon a-2b + Ribavirin
Normalized name: PEG-Interferon alfa-2A
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04868773
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral cabozantinib
Study: NCT04868773
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TAS-102 (trifluridine and tipiracil)
Study: NCT05716724
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
Study: NCT06167785
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg intravenously every 3 weeks
Study: NCT06167785
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg oral twice daily
Study: NCT06167785
Drug: Tislelizumab + Zanubrutinib
Normalized name: Tislelizumab
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
Study: NCT05862428
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
Study: NCT04957368
Drug: Nitrous Oxide 99 %
Normalized name: nitrous oxide 99 %
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
Study: NCT04957368
Drug: Oxygen + Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
Study: NCT06029530
Drug: Atropine Ophthalmic
Normalized name: atropine ophthalmic
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drops to be administered once daily
Study: NCT00002305
Drug: Flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002305
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002305
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06418113
Drug: Chemotherapy Stupp Protocol
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
Study: NCT05266040
Drug: Valacyclovir 500 MG
Normalized name: valacyclovir 500 MG
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Study: NCT05654454
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg
Study: NCT05654454
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2
Study: NCT04678869
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
Study: NCT04678869
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care antibiotic as per local policy
Study: NCT05165875
Drug: Hydrocortisone-Lidocaine
Normalized name: Hydrocortisone-Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
Study: NCT05654454
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6
Study: NCT05133349
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Study: NCT04625699
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
Study: NCT04625699
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of Tremelimumab 300 mg IV Day 1, q56 days
Study: NCT06238024
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose intravenous application
Study: NCT06238024
Drug: NaCl 0.9% 100ml
Normalized name: MORPHINE 1MG/ML NACL 0.9% 100ML
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose intravenous application
Study: NCT06525714
Drug: cisplatin oxaliplatin tegafur
Normalized name: tegafur
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg/m2 cisplatin at 43°C, with an infusion rate of 600 ml/min for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg/m2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \<1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \>1.5m2, 60 mg bid) from day 1 to 14.